# A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor

> **NCT05332574** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Genor Biopharma Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- NSCLC
- Other Solid Tumors

## Interventions

- **BIOLOGICAL:** GB263T

## Key facts

- **NCT ID:** NCT05332574
- **Lead sponsor:** Genor Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-17
- **Primary completion:** 2024-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2022-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05332574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05332574, "A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05332574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*